Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | Emerging immunotherapies for AML

Naval Daver • 17 Apr 2020
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Antibodies Blinatumomab Durvalumab Flotetuzumab Nivolumab Pembrolizumab

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the emerging immunotherapies for acute myeloid leukemia (AML). Specifically, T-cell enhancing therapies, macrophage-enhancing agents, bispecific antibodies and CAR-T cells are discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Naval Daver

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
Approaches to managing FLT3-mutant AML 12:59
Approaches to managing FLT3-mutant AML
Alexander Perl et al. • 20 Sep 2025
Ask the Expert: Naval Daver answers your AML questions at iwAL 2025 11:48
Ask the Expert: Naval Daver answers your AML questions at iwAL 2025
Naval Daver • 21 Sep 2025

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals